Safety and Efficacy Study for a New Antiviral Drug to Treat Genital Herpes Type 2

A Double-blind Randomized Placebo Controlled Dose-finding Trial to Investigate Different Doses of a New Antiviral Drug in Subjects With Genital HSV Type 2 Infection

The aim of the study is to find out whether AIC316 is safe and efficacious for the prevention of reactivation of genital herpes

Inclusion Criteria:

• Adult, Immunocompetent men and women in good health of any ethnic group
• History of recurrent episodes of genital herpes for at least 12 months
• Seropositive for Herpes Simplex Virus HSV Type 2
• Body Mass Index (BMI) between 18 and 35 kg/m2

Exclusion Criteria:

• Present episode of genital herpes
• Intake of systemic drug against HSV or any topical application against HSV within 7 days before randomization for the trial
• Intake of systemic corticosteroids, other immunomodulating agents or any investigational agent within 3 months before randomization for the trial
• Positive results in any of the virology tests for human immunodeficiency virus antibody (HIV-Ab), hepatitis C antibody (HCV-Ab), hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBc-Ab)